Moonlake Immunotherapeutics (MLTX) - News Archive

The biopharmaceutical industry is characterized by rapid innovation and intense competition, which can have significant implications for investors. A recent class action lawsuit filed against MoonLake Immunotherapeutics...

In the fast-evolving landscape of biopharmaceuticals, investor confidence plays a pivotal role in determining the future trajectories of companies engaged in developing novel therapeutics. One such entity, MoonLake Immu...

Navigating Legal Waters: MoonLake Immunotherapeutics Faces Class Action Amid Promising Financial Indicators On October 16, 2025, the Portnoy Law Firm announced a class action lawsuit on behalf of investors of MoonLake I...

MoonLake Immunotherapeutics to Host Capital Markets Day on April 29: What Investors Need to Know As the biopharmaceutical landscape continues to evolve, MoonLake Immunotherapeutics is gearing up to showcase its vision a...

MoonLake Immunotherapeutics Advances Phase 3 Trial Amidst Revenue Challenges: Unyielding Focus on Nanobody Sonelokimab for Psoriatic Arthritis In a significant stride towards addressing active psoriatic arthritis, MoonL...

MoonLake Immunotherapeutics: Bridging Innovation and Capital Markets in Psoriatic Arthritis Treatment In an era where biotechnology and pharmaceuticals are at the forefront of healthcare innovation, MoonLake Immunothera...

MoonLake Immunotherapeutics, a biopharmaceutical company focused on the development of innovative immunotherapies, recently announced positive regulatory feedback from both the U.S. Food and Drug Administration (FDA) an...